Investigating how prostate cancer can resist hormonal therapy without CYP17A1.
CYP17A1-independent androgen synthesis and prostate cancer resistance to next-generation hormonal therapy
This study is looking into why advanced prostate cancer sometimes stops responding to hormone treatments, even when a specific enzyme isn't involved, and aims to find new ways to help patients by understanding how cancer cells adapt and survive despite these therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Miami School of Medicine NIH-funded |
| Lab location | 1 site (Coral Gables, United States) |
| Project ID | NIH-11017804 on NIH RePORTER |
What this research studies
This research focuses on understanding how advanced prostate cancer can develop resistance to hormonal therapies, particularly when the CYP17A1 enzyme is not involved. The study aims to identify alternative pathways for androgen synthesis that contribute to this resistance, which could lead to new treatment strategies. By analyzing the role of specific enzymes and hormones in cancer progression, the research seeks to uncover mechanisms that allow cancer cells to thrive despite treatment. Patients may benefit from insights that could lead to more effective therapies for castration-resistant prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer who have shown resistance to standard androgen deprivation therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone hormonal therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with advanced prostate cancer who are resistant to current hormonal therapies.
How similar studies have performed: Previous research has shown success in targeting androgen synthesis pathways in prostate cancer, but this specific approach to CYP17A1-independent mechanisms is relatively novel.
Where this research is happening
Coral Gables, United States
- University of Miami School of Medicine — Coral Gables, United States (Active)
Researchers
- Principal investigator: Sharifi, Nima — University of Miami School of Medicine
- Study coordinator: Sharifi, Nima
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.